Why Does RGC Make Sense, For Now At Least?
RGC is unique, and in many ways we can understand why investors have begun to take notice of the business.
The Nasdaq Biotechnology Index has only risen by 2.69% year to far, but share prices have risen by 17.03%. Share prices fluctuate between $34.79 and $35.84 on average, with some investors setting their year range closer to $59.00 per share.
The company recorded a basic diluted loss per share of $0.29 for the six months from July 2021 to December 2021, compared to a loss per share of $0.03 for the corresponding period in 2020.
The loss may have been caused by the company's unexpected rise in operational costs, which increased by about 893% from $368,465 for the six months ended December 31, 2020, to $3,658,906 for the same period in 2021.
In comparison to $0.06 million in June 2021, the company declared cash available of $19 million in December 2021. The primary source of funds was the net proceeds of the company's IPO, which also included earnings from the selling of approximately 22.7 million extra shares.
When the company first went public in July 2021, share prices were far lower than they are now. A month later, in August 2021, share prices experienced a surge of up to 204% within a single trading session. Since becoming public, Regencell has successfully treated more than 88 COVID patients, with a 94% success rate in removing symptoms within 6 days. They also have continuing clinical investigations for ADHD/ASD, and they were added to the MSCI world microcap index. Additionally, RGC was among the Nasdaq's top-performing stocks in 2021, according to www.stockanalysis.com.
Regencell began conducting early trials for ADHD/ASD in late 2017. The stock was trading in the low $20 level at the time. Share prices increased to above $40 by mid-February 2022 before declining to the $20 area.
RGC has done admirably since April 2022, with share prices swinging above $30, despite choppy market conditions and unfavourable investor sentiment. Positive clinical outcomes pertaining to the RGC-COV19 TCM formula developed by the business are what have helped the stock performance recover.
In our opinion, when the business announces a second clinical examination of a standardised TCM formulation for the treatment of ADHD and ASD, RGC will see another price fluctuation. In order to provide an industry standard for therapy, dosage, side effects, and gauging patient response, Regencell has been working on this.
Investor interest has been maintained by RGC's steady performance and encouraging track record, which has remained largely unchanged. RGC may outperform weak market conditions for investors who can more easily handle tiny purchases.
RGC is unique, and in many ways we can understand why investors have begun to take notice of the business.
The Nasdaq Biotechnology Index has only risen by 2.69% year to far, but share prices have risen by 17.03%. Share prices fluctuate between $34.79 and $35.84 on average, with some investors setting their year range closer to $59.00 per share.
The company recorded a basic diluted loss per share of $0.29 for the six months from July 2021 to December 2021, compared to a loss per share of $0.03 for the corresponding period in 2020.
The loss may have been caused by the company's unexpected rise in operational costs, which increased by about 893% from $368,465 for the six months ended December 31, 2020, to $3,658,906 for the same period in 2021.
In comparison to $0.06 million in June 2021, the company declared cash available of $19 million in December 2021. The primary source of funds was the net proceeds of the company's IPO, which also included earnings from the selling of approximately 22.7 million extra shares.
When the company first went public in July 2021, share prices were far lower than they are now. A month later, in August 2021, share prices experienced a surge of up to 204% within a single trading session. Since becoming public, Regencell has successfully treated more than 88 COVID patients, with a 94% success rate in removing symptoms within 6 days. They also have continuing clinical investigations for ADHD/ASD, and they were added to the MSCI world microcap index. Additionally, RGC was among the Nasdaq's top-performing stocks in 2021, according to www.stockanalysis.com.
Regencell began conducting early trials for ADHD/ASD in late 2017. The stock was trading in the low $20 level at the time. Share prices increased to above $40 by mid-February 2022 before declining to the $20 area.
RGC has done admirably since April 2022, with share prices swinging above $30, despite choppy market conditions and unfavourable investor sentiment. Positive clinical outcomes pertaining to the RGC-COV19 TCM formula developed by the business are what have helped the stock performance recover.
In our opinion, when the business announces a second clinical examination of a standardised TCM formulation for the treatment of ADHD and ASD, RGC will see another price fluctuation. In order to provide an industry standard for therapy, dosage, side effects, and gauging patient response, Regencell has been working on this.
Investor interest has been maintained by RGC's steady performance and encouraging track record, which has remained largely unchanged. RGC may outperform weak market conditions for investors who can more easily handle tiny purchases.
https://seekingalpha.com/article/4534812-slow...bioscience
RGC is unique, and in many ways we can understand why investors have begun to take notice of the business.
The Nasdaq Biotechnology Index has only risen by 2.69% year to far, but share prices have risen by 17.03%. Share prices fluctuate between $34.79 and $35.84 on average, with some investors setting their year range closer to $59.00 per share.
The company recorded a basic diluted loss per share of $0.29 for the six months from July 2021 to December 2021, compared to a loss per share of $0.03 for the corresponding period in 2020.
The loss may have been caused by the company's unexpected rise in operational costs, which increased by about 893% from $368,465 for the six months ended December 31, 2020, to $3,658,906 for the same period in 2021.
In comparison to $0.06 million in June 2021, the company declared cash available of $19 million in December 2021. The primary source of funds was the net proceeds of the company's IPO, which also included earnings from the selling of approximately 22.7 million extra shares.
When the company first went public in July 2021, share prices were far lower than they are now. A month later, in August 2021, share prices experienced a surge of up to 204% within a single trading session. Since becoming public, Regencell has successfully treated more than 88 COVID patients, with a 94% success rate in removing symptoms within 6 days. They also have continuing clinical investigations for ADHD/ASD, and they were added to the MSCI world microcap index. Additionally, RGC was among the Nasdaq's top-performing stocks in 2021, according to www.stockanalysis.com.
Regencell began conducting early trials for ADHD/ASD in late 2017. The stock was trading in the low $20 level at the time. Share prices increased to above $40 by mid-February 2022 before declining to the $20 area.
RGC has done admirably since April 2022, with share prices swinging above $30, despite choppy market conditions and unfavourable investor sentiment. Positive clinical outcomes pertaining to the RGC-COV19 TCM formula developed by the business are what have helped the stock performance recover.
In our opinion, when the business announces a second clinical examination of a standardised TCM formulation for the treatment of ADHD and ASD, RGC will see another price fluctuation. In order to provide an industry standard for therapy, dosage, side effects, and gauging patient response, Regencell has been working on this.
Investor interest has been maintained by RGC's steady performance and encouraging track record, which has remained largely unchanged. RGC may outperform weak market conditions for investors who can more easily handle tiny purchases.
RGC is unique, and in many ways we can understand why investors have begun to take notice of the business.
The Nasdaq Biotechnology Index has only risen by 2.69% year to far, but share prices have risen by 17.03%. Share prices fluctuate between $34.79 and $35.84 on average, with some investors setting their year range closer to $59.00 per share.
The company recorded a basic diluted loss per share of $0.29 for the six months from July 2021 to December 2021, compared to a loss per share of $0.03 for the corresponding period in 2020.
The loss may have been caused by the company's unexpected rise in operational costs, which increased by about 893% from $368,465 for the six months ended December 31, 2020, to $3,658,906 for the same period in 2021.
In comparison to $0.06 million in June 2021, the company declared cash available of $19 million in December 2021. The primary source of funds was the net proceeds of the company's IPO, which also included earnings from the selling of approximately 22.7 million extra shares.
When the company first went public in July 2021, share prices were far lower than they are now. A month later, in August 2021, share prices experienced a surge of up to 204% within a single trading session. Since becoming public, Regencell has successfully treated more than 88 COVID patients, with a 94% success rate in removing symptoms within 6 days. They also have continuing clinical investigations for ADHD/ASD, and they were added to the MSCI world microcap index. Additionally, RGC was among the Nasdaq's top-performing stocks in 2021, according to www.stockanalysis.com.
Regencell began conducting early trials for ADHD/ASD in late 2017. The stock was trading in the low $20 level at the time. Share prices increased to above $40 by mid-February 2022 before declining to the $20 area.
RGC has done admirably since April 2022, with share prices swinging above $30, despite choppy market conditions and unfavourable investor sentiment. Positive clinical outcomes pertaining to the RGC-COV19 TCM formula developed by the business are what have helped the stock performance recover.
In our opinion, when the business announces a second clinical examination of a standardised TCM formulation for the treatment of ADHD and ASD, RGC will see another price fluctuation. In order to provide an industry standard for therapy, dosage, side effects, and gauging patient response, Regencell has been working on this.
Investor interest has been maintained by RGC's steady performance and encouraging track record, which has remained largely unchanged. RGC may outperform weak market conditions for investors who can more easily handle tiny purchases.
https://seekingalpha.com/article/4534812-slow...bioscience
